Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 96 week study comparing the antiviral efficacy and safety of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with fixed dose tenofovir-emtricitabine [emtricitabine/tenofovir-disoproxil-fumarate] in HIV-1 infected treatment in naive subjects

Next Previous
X
Search
Trial Profile

A 96 week study comparing the antiviral efficacy and safety of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with fixed dose tenofovir-emtricitabine [emtricitabine/tenofovir-disoproxil-fumarate] in HIV-1 infected treatment in naive subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir (Primary) ; Ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms CASTLE
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 12 Feb 2014 Results from a sub-group analysis published in the Clinical Drug Investigation.
    • 20 Jul 2011 BMD outcomes from a subgroup analysis presented at the 6th International AIDS Society Conference on HIV Pathogenesis and Treatment.
    • 09 Dec 2010 Results from a comparative gender analysis have been published in the Journal of Antimicrobial Chemotherapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top